Eli Lilly & Co. (LLY:US) had the second-steepest retreat in the S&P 500, losing 3.9 percent to $35.13. The maker of the antipsychotic Zyprexa said 2009 profit excluding some costs probably won’t exceed $4.40 a share. Analysts polled by Bloomberg estimated $4.42 per share on average.